Imaging embedded in early decision-making.
We are a science-first imaging Core Lab built for Phase I–II clinical trials, combining deep medical imaging expertise with purpose-built digital infrastructure to reduce uncertainty while biology is still actionable.
CRO, intentionally
focused.
Fidēs is a dedicated imaging CRO built for the complexity of early clinical development.
The Science
Genuine depth of scientific and medical expertise — grounded in biology and physiology, not just image handling.
True Agility
Adaptive by design. We engage on the best path forward based on what the data shows — not on what was planned before the study began.
Scientific integrity
If it is not working, we will tell you — and we will collaborate to find a better experiment. Clarity over reassurance, always.
Patient-First
Every study we support is ultimately about bringing better therapies to patients more efficiently. That purpose guides every decision we make.
Mission, Vision & Values.
Our mission, vision and values reflect our belief that the standard of what sponsors should expect from an imaging partner can, and should be higher.
Accelerate efficient and reliable drug development.
To accelerate efficient and reliable drug development through advanced imaging technology, delivering insights that improve patient outcomes.
Better imaging science in every development decision.
To improve patient outcomes and quality of life by bringing leading imaging science, best-in-class tools and trusted expertise to drug development across therapy areas.
Transparency, excellence, integrity and respect.
Fidēs embraces innovation, fosters collaboration and strives for excellence in clinical trial delivery. Guided by transparency, operational excellence, respect and integrity — we deliver powerful datasets and analyses throughout the clinical trial process.
We are intentionally not for everyone.
Fidēs was built for a specific problem in drug development: early-phase programs where imaging is central to understanding biology and where decisions cannot wait until the end of a study. We work most effectively with sponsors who share that urgency around early learning.
We focus where complexity is highest, programs exploring novel mechanisms, non-standard endpoints, and therapeutic areas where physiology and function are central to interpretation. This focus allows us to deliver depth where generic CRO models often struggle.
We are intentionally focused. If scale and speed are the only priorities, we are unlikely to be the best partner, and that clarity benefits everyone.
-
Scientific uncertainty is a primary development risk Imaging interpretation requires biological and physiological context, not just protocol compliance.
-
Imaging must actively inform development strategy Not as a downstream reporting service, but as a live scientific input while there is still time to act on what you learn.
-
Standard endpoints alone may not tell the full story You need augmented or additive imaging measures that go beyond what established frameworks capture.
-
Transparency and early learning are valued over late correction You want a partner who will tell you what they see, including when findings are uncomfortable.
A small, focused team with deep expertise, working across imaging science, clinical operations, platform development and commercial partnerships.
Built to operate differently.
Adaptive and collaborative
We engage with sponsors as scientific partners, not service providers. Study designs evolve with the data — and we are structured to respond when they do.
Driven by technology, not legacy systems
Aperis, our proprietary imaging platform, replaces manual, fragmented workflows with embedded automation and real-time data access built around how scientists actually work.
Transparent progress, always
Sponsors access imaging data, annotations and analyses continuously throughout a study — not only at formal milestones. Visibility is structural, not a reporting feature.
Designed for complex and challenging areas
Including rare disease, paediatric research and therapeutic areas where standard endpoints do not fully capture biological response. Complexity is where we are most useful.
Built from Motilent’s platform and science.
Years of GI imaging science from Motilent
Research projects and clinical trials on the platform
Listed imaging platform: EntrolyticsMD
Therapy areas supported across the Fidēs network
Fidēs is a spin-out from Motilent — a medical imaging software company with over a decade of focused work on quantitative GI imaging, proprietary motion analysis tools and a platform used across more than 500 research projects and clinical trials globally.
That foundation gives Fidēs a mature, clinically validated technology base in Aperis, and native scientific depth in gastroenterology and hepatology. It also gives us a network of leading KOLs who contribute to study design, endpoint development and scientific oversight across therapy areas.
Fidēs is independent and therapy-agnostic. Our focus extends across oncology, cardiovascular, CNS, renal and metabolic disease, with scientific fit, not inherited specialism, guiding where we work.
Trusted by biopharma and biotech.
From emerging biotech to established pharma, we partner with teams navigating complex early-phase programs where imaging insight matters most.
The thinking behind Aperis — built for how scientists actually interrogate imaging mid-study.
Read more
Functional cardiac motion as an imaging endpoint in early cardiovascular development.
Read more
The Fidēs team will be at ECCO 2025 in Stockholm — book a meeting to talk early-phase GI imaging.
Read more
The decision problem at the heart of IBD trials, and how imaging can de-risk it earlier.
Read more
Rethinking response assessment in oncology with additive, mechanistically relevant imaging endpoints.
Read more
How Aperis gives sponsors continuous visibility of imaging data throughout a Phase I study.
Read more
Why motion and motility are powerful, under-used imaging endpoints in early-phase trials.
Read more
Fidēs Imaging opens its doors as a science-first imaging Core Lab focused on early-phase clinical development.
Read moreWhere would you like to go next?
Our team
Meet the scientists, clinicians and operational specialists who make up the Fidēs team — and the KOL network that brings additional depth across therapy areas.
Meet the TeamCapabilities
From study design through to final report — see how Fidēs supports every stage of the imaging lifecycle in early-phase clinical development.
View CapabilitiesGet in Touch
Tell us about your program. We are happy to have a no-obligation conversation about whether Fidēs is the right partner for your study.
Contact Us